Cargando…

Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease

INTRODUCTION: Insight into the relationship between concepts that matter to the people affected by Alzheimer’s disease (AD) and the clinical outcome assessments (COAs) commonly used in AD clinical studies is limited. Phases 1 and 2 of the What Matters Most (WMM) study series identified and quantitat...

Descripción completa

Detalles Bibliográficos
Autores principales: DiBenedetti, Dana B., Menne, Heather, Paulsen, Russ, Krasa, Holly B., Vradenburg, George, Comer, Meryl, Callahan, Leigh F., Winfield, John, Potashman, Michele, Heithoff, Kim, Hartry, Ann, Oberdhan, Dorothee, Wilson, Hilary, Hoffman, Deborah L., Wieberg, Dan, Kremer, Ian N., Taylor, Geraldine A., Taylor, James M., Lappin, Debra, Martin, Allison D., Hauber, Brett, Romano, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043075/
https://www.ncbi.nlm.nih.gov/pubmed/36790638
http://dx.doi.org/10.1007/s40120-023-00443-2
_version_ 1784913067137564672
author DiBenedetti, Dana B.
Menne, Heather
Paulsen, Russ
Krasa, Holly B.
Vradenburg, George
Comer, Meryl
Callahan, Leigh F.
Winfield, John
Potashman, Michele
Heithoff, Kim
Hartry, Ann
Oberdhan, Dorothee
Wilson, Hilary
Hoffman, Deborah L.
Wieberg, Dan
Kremer, Ian N.
Taylor, Geraldine A.
Taylor, James M.
Lappin, Debra
Martin, Allison D.
Hauber, Brett
Romano, Carla
author_facet DiBenedetti, Dana B.
Menne, Heather
Paulsen, Russ
Krasa, Holly B.
Vradenburg, George
Comer, Meryl
Callahan, Leigh F.
Winfield, John
Potashman, Michele
Heithoff, Kim
Hartry, Ann
Oberdhan, Dorothee
Wilson, Hilary
Hoffman, Deborah L.
Wieberg, Dan
Kremer, Ian N.
Taylor, Geraldine A.
Taylor, James M.
Lappin, Debra
Martin, Allison D.
Hauber, Brett
Romano, Carla
author_sort DiBenedetti, Dana B.
collection PubMed
description INTRODUCTION: Insight into the relationship between concepts that matter to the people affected by Alzheimer’s disease (AD) and the clinical outcome assessments (COAs) commonly used in AD clinical studies is limited. Phases 1 and 2 of the What Matters Most (WMM) study series identified and quantitatively confirmed 42 treatment-related outcomes that are important to people affected by AD. METHODS: We compared WMM concepts rated as “very important” or higher to items included in COAs used commonly in AD studies. RESULTS: Twenty COAs designed to assess signs, symptoms, and impacts across the spectrum of AD were selected for review. Among these 20 COAs, only 5 reflected 12 or more WMM concepts [Integrated Alzheimer's Disease Rating Scale (iADRS), Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory (ADCS-ADL), Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory–Mild Cognitive Impairment (ADCS-ADL-MCI), Alzheimer's Disease Composite Scores (ADCOMS), and Clinical Dementia Rating; Clinical Dementia Rating-Sum of Boxes (CDR/CDR-SB)]. Multiple symptoms and impacts of AD identified as important and meaningful in the WMM studies map only indirectly at best to 7 of the 20 most widely used COAs. CONCLUSION: While many frequently used COAs in AD capture some concepts identified as important to AD populations and their care partners, overlap between any single measure and the concepts that matter to people affected by AD is limited. The highest singly matched COA reflects fewer than half (45%) of WMM concepts. Use of multiple COAs expands coverage of meaningful concepts. Future research should explore the content validity of AD COAs planned for AD trials based on further confirmation of the ecological validity of the WMM items. This research should inform development and use of core outcome sets that capture WMM items and selection or development of new companion tools to fully demonstrate clinically meaningful outcomes spanning WMM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-023-00443-2.
format Online
Article
Text
id pubmed-10043075
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-100430752023-03-29 Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease DiBenedetti, Dana B. Menne, Heather Paulsen, Russ Krasa, Holly B. Vradenburg, George Comer, Meryl Callahan, Leigh F. Winfield, John Potashman, Michele Heithoff, Kim Hartry, Ann Oberdhan, Dorothee Wilson, Hilary Hoffman, Deborah L. Wieberg, Dan Kremer, Ian N. Taylor, Geraldine A. Taylor, James M. Lappin, Debra Martin, Allison D. Hauber, Brett Romano, Carla Neurol Ther Original Research INTRODUCTION: Insight into the relationship between concepts that matter to the people affected by Alzheimer’s disease (AD) and the clinical outcome assessments (COAs) commonly used in AD clinical studies is limited. Phases 1 and 2 of the What Matters Most (WMM) study series identified and quantitatively confirmed 42 treatment-related outcomes that are important to people affected by AD. METHODS: We compared WMM concepts rated as “very important” or higher to items included in COAs used commonly in AD studies. RESULTS: Twenty COAs designed to assess signs, symptoms, and impacts across the spectrum of AD were selected for review. Among these 20 COAs, only 5 reflected 12 or more WMM concepts [Integrated Alzheimer's Disease Rating Scale (iADRS), Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory (ADCS-ADL), Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory–Mild Cognitive Impairment (ADCS-ADL-MCI), Alzheimer's Disease Composite Scores (ADCOMS), and Clinical Dementia Rating; Clinical Dementia Rating-Sum of Boxes (CDR/CDR-SB)]. Multiple symptoms and impacts of AD identified as important and meaningful in the WMM studies map only indirectly at best to 7 of the 20 most widely used COAs. CONCLUSION: While many frequently used COAs in AD capture some concepts identified as important to AD populations and their care partners, overlap between any single measure and the concepts that matter to people affected by AD is limited. The highest singly matched COA reflects fewer than half (45%) of WMM concepts. Use of multiple COAs expands coverage of meaningful concepts. Future research should explore the content validity of AD COAs planned for AD trials based on further confirmation of the ecological validity of the WMM items. This research should inform development and use of core outcome sets that capture WMM items and selection or development of new companion tools to fully demonstrate clinically meaningful outcomes spanning WMM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-023-00443-2. Springer Healthcare 2023-02-15 /pmc/articles/PMC10043075/ /pubmed/36790638 http://dx.doi.org/10.1007/s40120-023-00443-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
DiBenedetti, Dana B.
Menne, Heather
Paulsen, Russ
Krasa, Holly B.
Vradenburg, George
Comer, Meryl
Callahan, Leigh F.
Winfield, John
Potashman, Michele
Heithoff, Kim
Hartry, Ann
Oberdhan, Dorothee
Wilson, Hilary
Hoffman, Deborah L.
Wieberg, Dan
Kremer, Ian N.
Taylor, Geraldine A.
Taylor, James M.
Lappin, Debra
Martin, Allison D.
Hauber, Brett
Romano, Carla
Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease
title Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease
title_full Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease
title_fullStr Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease
title_full_unstemmed Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease
title_short Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease
title_sort technical review of clinical outcomes assessments across the continuum of alzheimer's disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043075/
https://www.ncbi.nlm.nih.gov/pubmed/36790638
http://dx.doi.org/10.1007/s40120-023-00443-2
work_keys_str_mv AT dibenedettidanab technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT menneheather technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT paulsenruss technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT krasahollyb technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT vradenburggeorge technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT comermeryl technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT callahanleighf technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT winfieldjohn technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT potashmanmichele technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT heithoffkim technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT hartryann technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT oberdhandorothee technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT wilsonhilary technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT hoffmandeborahl technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT wiebergdan technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT kremeriann technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT taylorgeraldinea technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT taylorjamesm technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT lappindebra technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT martinallisond technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT hauberbrett technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease
AT romanocarla technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease